To Evaluate the Clearance Rate of Uremic Toxin by HFR
Conditions
Brief summary
1.1Primary Objective To evaluate the clearance rate of uremic toxin β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) by HFR. 1.2Secondary Objectives 1.1.1 To evaluate the clearance of low molecular weight uremic toxin urea (spKt/V, URR). 1.1.2 To evaluate the clearance of other middle molecules and macromolecular uremic toxins, including α1-microglobulin (α1-MG), κ-free light chain (κFLC), homocysteine (Hcy), interleukin-6 (IL-6), p-cresol, YKL-40, complement factor D (CFD), leptin, hippuric acid, trimethylamine oxide (TMAO), asymmetric dimethylarginine (ADMA), tumor necrosis factor-α (TNF- α), myoglobin, fibroblast growth factor 23 (FGF23) and intact parathyroid hormone (iPTH). 1.1.3 To evaluate the clearance of serum albumin, branched chain amino acids and vitamins A, C, E. 1.1.4 To evaluate the comfort of HFR treatment for MHD patients.
Interventions
OTHERHFR
patient received HFR treatment
Sponsors
RenJi Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18-75 years old, regardless of gender. * MHD for at least 3 months, and blood purification treatment for 3 times per week. * The vascular access is autogenous arteriovenous fistula or artificial blood vessels，with a blood flow ≥200mL/min. * spKt/V≥1.2. * Patients who signed the informed consent form (ICF) voluntarily.
Exclusion criteria
* Patients who have participated in other interventional clinical trials within a month. * Pregnant or lactating women. * Patients of NYHA class IV or occurred acute coronary syndrome or myocardial infarction in 3 months before the start of the study. * Patients with active hemorrhage in 2 weeks (e.g., cerebral hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage, etc.). * Patients with unstable blood pressure (pre-dialysis systolic blood pressure ≥180 or ≤90mmHg, pre-dialysis diastolic blood pressure ≥100 or ≤60mmHg), severe anemia (hemoglobin ≤60g/L), and high risk of blood coagulation (e.g., albumin ≤25g/L or hemoglobin ≥140g/L). * Patients with severe infection (the level of hypersensitive C-reactive protein(hsCRP) ≥ 10×upper limit of normal). * Patients with a history of drug addiction or severe mental disorders. * Other conditions in which the investigators reject patients to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) | 1 day | The concentrations of β2-microglobulin (β2-MG), indoxyl sulfate and λ-free light chain (λFLC) were measured before and after HFR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Single-compartment urea clearance index (spKt/V), Urea Reduction Ratio | 1 day | Calculate spKt/V and Urea Reduction Ratio. |
| other middle molecules and macromolecular uremic including α1-MG, κFLC, Hcy, IL-6, p-cresol, YKL-40, CFD, leptin, hippuric acid, TMAO, ADMA, TNF-α, myoglobin, FGF23 and iPTH | 1 day | The concentrations of other middle molecules and macromolecular uremic were measured before and after HFR |
| serum albumin, branched chain amino acids and vitamins A, C, E | 1 day | The concentrations of serum albumin, branched chain amino acids and vitamins A, C, E before and after HFR |
| the comfort of HFR treatment | 1 day | The dialysis comfort score was used for evaluation |
Contacts
Primary ContactRenhua Lu
Outcome results
None listed